Business Address:
`
`Date of Birth:
`
`Place of Birth:
`
`Citizenship:
`
`Positions:
`7/90-12/96
`
`7/90-2011
`
`7/96- 10/00
`
`1/97-6/04
`
`4/98-8/98
`
`10/00-12/20
`
`7/04-present
`
`Education:
`1973-1975
`1975-1977
`
`1977-1979
`1979-1984
`
`CURRICULUM VITAE
`
`ROBERTS. NEGRIN, M.D.
`
`Blood and Marrow Transplantation & Cellular Therapy
`Stanford University Hospital
`Stanford, CA 94305
`(650) 723-0822
`(650) 724-6182 (FAX)
`email: negrs@stanford.edu
`
`March 6, 1955
`
`Plainfield, New Jersey
`
`USA
`
`Assistant Professor of Medicine
`Stanford University
`Medical Director
`Clinical Bone Marrow Transplant Laboratory
`Stanford University Hospital
`Associate Director
`Division of Bone Marrow Transplantation
`Stanford University
`Associate Professor of Medicine
`Stanford University
`Visiting Professor
`University of Perugia, Perugia, Italy
`Chief
`Division of Blood and Marrow Transplantation
`Stanford University
`Professor of Medicine
`Stanford University
`
`University of California, San Diego, CA
`University of California, Berkeley, CA
`AB. Biochemistry
`University of Wisconsin, Madison, WI
`Harvard Medical School - Massachusetts
`Institute of Technology, Division of Health Sciences and Technology, M.D.
`
`Postgraduate Training:
`1984-1985
`1985-1987
`1987-1990
`
`Intern in Medicine, Stanford University
`Resident in Medicine, Stanford University
`Fellowship in Hematology, Stanford University
`
`1
`
`UPenn Ex. 2066
`Miltenyi v. UPenn
`IPR2022-00855
`
`

`

`Awards:
`1984
`1988-1991
`1992
`1993-1996
`
`2004-2009
`
`2005
`2007
`2008
`2018
`
`2018
`
`Grant Support
`
`ACTIVE
`
`Graduated cum laude, Harvard Medical School
`Damon Runyon-Walter Winchell Cancer Fund Fellowship
`Joseph H. Leutje Faculty Scholar
`Fellow of the Jose Carreras International Leukemia Foundation,
`FIJC-92/INT-2
`Doris Duke Distinguished Clinical Scientist Award. Regulatory T Cells in Bone
`Marrow Transplantation.
`Leukemia and Lymphoma Society, “Outstanding Volunteer”.
`Gerhard Schmidt Memorial Lecture, City of Hope, Duarte, CA.
`Association of American Physicians (AAP)
`E. Donnall Thomas Lecture, American Society of Blood and Marrow
`Transplantation
`Richard O’Reilly Lecture, Memorial Sloan Cancer Center
`
`P01CA049605 (Negrin)
`NIH/National Cancer Institute
`Bone Marrow Grafting for Leukemia and Lymphoma
`Role: Principal Investigator, Project 1 Leader, Core A Director.
`The major goals of this project are to improve the outcome for patients with hematologic malignancies undergoing
`autologous and allogeneic transplantation. This program project grant consists of 4 projects and 4 cores focusing
`on critical issues in the transplantation setting including detection and eradication of minimal residual disease,
`control of graft-vs-host disease, enhancing immune reconstitution.
`
`04/15/89-06/30/24
`$1,732,410
`
`2.70 calendar
`
`UG1 HL069291 (Lowsky)
`NIH/National Heart, Lung and Blood Institute
`BMT Clinical Trial Network at Stanford
`Role: Co-Investigator
`The major goals of this project are to perform clinical trials in the BMT Clinical Trial Network related to the field of
`hematopoietic cell transplantation.
`
`7/01/11-06/30/24
`$7,182
`
`0.36 calendar
`
`Memberships in Professional Organizations:
`American Society of Hematology
`International Society of Experimental Hematology
`American College of Physicians
`American Association for the Advancement of Science
`International Society for Cellular Therapy
`American Society for Blood and Marrow Transplantation
`Western Society for Clinical Investigation
`
`Board Certification:
`
`2
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UPenn Ex. 2066
`Miltenyi v. UPenn
`IPR2022-00855
`
`

`

`Internal Medicine (1987)
`Hematology (1992)
`Hematology Re-Certification (2007)
`
`1995-2000
`1995-1997
`1997-1999
`1997-1998
`1998
`
`1999
`1999-2000
`
`1999-2002
`2000-2003
`2000-2002
`2000–2005
`2001-2005
`2002-2005
`2002-2004
`2002-2007
`2003-2010
`2003-2004
`
`Committees and Leadership Positions:
`1990-present
`Bone Marrow Transplantation Review Committee
`1991-present
`Stanford University School of Medicine Admissions Review Board
`1991-1993
`Scientific American Medicine Health Assessment Program Panel of
`Examiners
`American Cancer Society Institutional Grant Review Committee
`Department of Medicine Advisory Committee
`Stem Cell Evaluation Committee of ISHAGE, Committee Chairperson
`American Society of Clinical Oncology Chemoprotectants Expert Panel
`ASH Educational Session Chair, Bone Marrow Transplantation for
`Malignant Diseases
`ASCO Educational Session, Immunotherapy
`President-Elect, International Society of Hematotherapy and Graft Engineering
`(ISHAGE)
`Stanford University School of Medicine Admissions Committee
`Appointments and Promotions Committee, Department of Medicine
`President, International Society of Cellular Therapy (formerly ISHAGE)
`NCI Committee D
`Board of Directors, American Society of Blood and Marrow Transplantation
`Faculty Senator, Stanford University School of Medicine
`Chair of the Advisory Board, International Society of Cellular Therapy
`American Society of Hematology – Publications Committee
`Transfusion Committee – Stanford University Hospital
`Chair of Organizing Committee for American Society of Blood and Marrow
`Transplantation Annual Meeting 2/04 in Orlando, Florida
`American Society of Hematology – Scientific Sub-Committee on Transplantation
`Biology
`Vice President – American Society of Blood and Marrow Transplantation
`Chair, NCI Sub-Committee D
`President-Elect, American Society of Blood and Marrow Transplantation
`President, American Society of Blood and Marrow Transplantation
`Chair, American Society of Hematology – Scientific Sub-Committtee on
`Transplantation Biology
`NHLBI Training Programs (T32 and T35) Study Section
`American Board of Internal Medicine Hematology Panel
`American Society of Blood and Marrow Transplantation 2011 Annual Meeting
`Organizing Committee
`NCI Clinical Oncology Study Section
`Leukemia and Lymphoma Society Medical and Scientific Affairs Committee
`Immune Tolerance Network Executive Committee
`Chair, Clinical Oncology Study Section
`Chair, Division of Infectious Diseases Search Committee
`Cancer Consortium External Advisory Board, Fred Hutchinson Cancer Institute,
`University of Washington
`Boston Children’s/DFCI Stem Cell Transplant Program Strategic Advisory Board
`
`2003-2008
`
`2004-2005
`2004-2005
`2005-2006
`2006-2007
`2006-2008
`
`2006
`2008-2014
`2010
`
`2010-2014
`2011-2012
`2012-2014
`2012-2014
`2015-2016
`2018-present
`
`2019-present
`
`Editorial Boards:
`1992-1995
`1993-1996
`1996-1999
`1998-2003
`
`Hematopoietic Therapy Index and Reviews
`Cytokines in Hematology/Oncology
`Hematological Oncology, Associate Editor
`Biology of Blood and Marrow Transplantation
`
`3
`
`
`
`
`
`
`
`UPenn Ex. 2066
`Miltenyi v. UPenn
`IPR2022-00855
`
`

`

`1999-present
`2003-2009
`2005-2009
`2008-2010
`2009-2016
`2016-2021
`
`Cytotherapy
`Associate Editor, Biology of Blood and Marrow Transplantation
`Blood
`Journal of Clinical Oncology
`Associate Editor, Blood
`Founding Editor-in-Chief, Blood Advances
`
`Selected Invited Lectures:
`11/90 Second Bone Marrow Transplant Symposium at Stanford University, Stanford, CA: Bone Marrow Purging.
`
`4/91
`
`Scripps Symposium, San Diego, CA: Update on Oncology - Hematopoietic Growth Factors.
`
`10/91 Children’s Hospital of Philadelphia, Philadelphia, PA: Grand Rounds: Colony Stimulating Factors.
`
`7/92
`
`Leukemia 92, Genoa, Italy: Use of G-CSF for the Treatment of Myelodysplastic Syndromes.
`
`6/93
`
`2nd Annual Symposium on Chronic Myelogenous Leukemia, Vancouver, Canada: Isolation of purged
`bcr/abl negative stem cells in CML.
`
`11/94 Third Biennial Bone Marrow and Stem Cell Transplantation Symposium, Stanford, CA: Chronic Myelogenous
`Leukemia.
`3/95 3rd International Symposium on Recent Advances in Hematopoietic Stem Cell Transplantation - Clinical
`Progress, New Technology and Gene Therapy, San Diego, CA: Transplantation of Enriched and Purged
`Peripheral Blood Progenitor Cells from a Single Apheresis Product.
`
`10/95 1st International Symposium on Allogeneic Peripheral Blood Progenitor Cell Transplantation, Geneva,
`Switzerland: Transplantation of Allogeneic Low Density Peripheral Blood Stem Cells.
`
`1/96
`
`Keystone Symposium, Keystone, CO: Blood and Bone Marrow Transplants.
`
`2/96 Third International Freiburg Symposium on Molecular Hematology: Cells, Genes and Therapy, Freiberg,
`Germany: Biology of Cytokine Induced Killer Cells.
`
`6/97
`
`ISHAGE Annual Meeting, Bordeaux, France: Autologous Transplantation for Non-Hodgkin’s Lymphoma.
`
`1/98
`
`Keystone Symposium, Keystone, CO: Cellular Immunity Following Transplantation.
`
`12/98 American Society of Hematology Educational Session, St. Louis, MO (Session Chair): Immunotherapeutic
`Principles and Practice.
`7th International Symposium on Recent Advances in Hematopoietic Stem Cell Transplantation, San Diego,
`CA: Identification of Tumor Cells.
`American Society of Clinical Oncology Educational Session, Atlanta, GA: Immunotherapy.
`
`5/99
`
`5/99
`
`10/99 Advances in Hematology, Stanford University, Stanford, CA: Diagnosis, Management and Treatment of
`Chronic Myelogenous Leukemia.
`10/00 Seventh Biennial National Symposium on Bone Marrow and Stem Cell Transplantation, Stanford, CA:
`Transplantation of Haploidentical Stem Cell Grafts.
`
`10/00 International Symposium on Molecular Radiology, Marburg, Germany: Visualizing In Vivo Gene Expression
`Using Bioluminescence.
`
`2/01 American Society for Blood and Marrow Transplantation Annual Meeting, Keystone, CO: Visualizing Tumor
`Growth and Response to Therapy in Living Animals.
`
`3/01 9th International Symposium on Recent Advances in Hematopoietic Cell Transplantation, San Diego, CA:
`Vaccine after BMT for NHL?
`
`4
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UPenn Ex. 2066
`Miltenyi v. UPenn
`IPR2022-00855
`
`

`

`7/01
`
`1/02
`
`2/02
`
`3/02
`
`Santa Clara Valley Medical Center, Grand Rounds, San Jose, CA: Autologous Hematopoietic Cell
`Transplantation – ‘The Next Steps’.
`
`3rd International Workshop on Non-Myeloablative Stem Cell Transplantation, Captiva Island, FL: T-NK Cell
`Infusions – Preclinical and Clinical Experience.
`
`American Society for Blood and Marrow Transplantation Annual Meeting, Orlando, FL: Visualization of In
`Vivo Mechanisms of NK-T Cell-Based Immunotherapy.
`
`BioX Symposium: Follow Cells and Molecules In Vivo: Stanford, CA: Where Immune Cells Go and What
`They Do When They Get There: Imaging as a Guide for Cell-Based Therapeutics.
`
`6/02
`
`American Society of Gene Therapy, Boston, MA: Clinical Applications of Purified Hematopoietic Stem Cells.
`
`7/02
`
`8/02
`
`International Society of Experimental Hematology Annual Meeting, Montreal, Canada: Visualization of
`Tumor and Effector Cell Trafficking in Hematologic Malignancies.
`
`XIX International Congress of the Transplantation Society, Miami, FL: Monotoring Lymphocyte Trafficking
`with Bioluminescence.
`
`9/02
`
`Transplantation in Hematology and Oncology, Muenster, Germany: NK-T Cell Based Immunotherapy.
`
`10/02 Eighth Biennial National Symposium on Hematopoietic Cell Transplantation, Stanford, CA: Graft-Versus-
`Tumor Mechanisms and Strategies.
`
`12/02 Eleventh International ABMT Symposium on Stem Cell and Targeted Therapy, Arlington, TX: T-Cell
`Variant/NK Cell Anti-Cancer Therapy.
`
`2/03
`
`American Society for Blood and Marrow Transplantation Annual Meeting, Keystone, CO: Transplant
`Regimens using Cellular Therapy for Hematologic Malignancies.
`
`3/03 Community Hospital of the Monterey Peninsula Grand Rounds, Monterey, CA: Mini Stem Cell Transplants.
`5/03 Mount Sinai School of Medicine, Hematology/Oncology Grand Rounds, New York, NY: Visualizing Graft-
`Versus-Tumor and Graft-Versus-Host Reactions.
`
`5/03
`
`International Society of Cellular Therapy Annual Meeting, Phoenix, AZ: Real-Time Modeling of Adoptive
`Immunotherapy.
`
`10/03 Advances in Hematology, Stanford University, Stanford, CA. Update on Allogeneic Transplantation for
`Hematologic Malignancies.
`
`10/03 Hematology/Oncology Grand Rounds. Dana Farber Cancer Institute, Boston, MA. Visualizing Graft-
`Versus-Tumor and Graft-Versus-Host Reactions.
`
`1/04 Hematology/Oncology Grand Rounds. University of Michigan, Ann Arbor, MI. Visualising Graft-Versus-
`Tumor and Graft-Versus-Host Disease Reactions.
`
`3/04 Hematology/BMT Conference, City of Hope National Medical Center, Duarte, CA. Immune regulation as a
`Strategy for Control of Graft-Versus-Host Disease.
`
`4/04
`
`7/04
`
`9/04
`
`San Ramon Regional Medical Center, San Ramon, CA. New Directions in Hematopoietic Cell
`Transplantation.
`
`4th Annual Conference of FOCIS, Montreal, Canada. Visualizing Graft-vs-Host and Graft-vs-Tumor
`Reactions.
`
`6th Annual Symposium on Emerging Technologies in Cancer Research, Roswell Park Cancer Institute,
`Buffalo, NY. Plenary lecture: Bioluminescence Imaging in Cancer Research.
`
`5
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UPenn Ex. 2066
`Miltenyi v. UPenn
`IPR2022-00855
`
`

`

`10/04 New Perspectives in Allogeneic Transplantation of Hematopoietic Cells, Milan, Italy. Preservation of graft-
`versus-tumor activity and inhibition of graft-versus-host disease using CD4+CD25+ regulatory T cells.
`
`11/04 Visualizing Graft-versus-Host and Graft-versus-Tumor Reactions, University of Nevada at Reno, Reno,
`Nevada.
`
`12/04 American Society of Hematology, San Diego, CA. Scientific Sub-Committee on Lymphocyte Trafficking and
`Homing. Visualization of T Cell Trafficking in GVHD and GVL.
`
`2/05 Nursing Symposium at American Society of Blood and Marrow Transplantation. Hematopoietic Cell
`Transplantation, Where have we gone, Where are we going? Keystone, Colorado.
`
`2/05
`
`Tandem BMT Meetings, Scientific Session on Imaging in Hematopoietic Cell Transplantation (Chair).
`Visualization of Graft-versus-Host Disease and Graft-versus-Tumor Reactions. Keystone, Colorado.
`
`5/05
`
`5th Annual Conference of FOCIS, Boston, MA. In Vivo Imaging.
`
`6/05
`
`10th Annual Meeting of the European Hematology Association, Stockholm, Sweden. Plenary Session.
`Visualization of Graft-vs-Host Disease and Graft-vs-Tumor Reactions.
`
`8/05 University of Miami, Miama, Florida. Visualization of T cell Trafficking in Graft-versus-Host Disease.
`
`9/05
`
`Imaging in 2020, Jackson Hole, WY. Visualization of Immune Reactions.
`
`10/05 California Institute for Regenerative Medicine, San Francisco, CA. Stem Cell Research: Charting New
`Directions in California. Hematopoietic Cell Transplantation, Where We Have Been, Where We Are Going.
`
`10/05 Cellular Therapy of Autoimmune Diseases, Newport Beach, CA. Biology of Tregs.
`
`10/05 Dana Farber Cancer Institute, Boston, MA. Hematology/Oncology Grand Rounds. Visualization of Graft- vs-
`Host and Graft-vs-Tumor Reactions.
`
`10/05 Ohio State University, Columbus, Ohio. Hematology/Oncology Grand Rounds. Immune Regulatoin and
`Control of Graft-versus-Host Disease.
`
`11/05 Stanford University, Palo Alto, CA. Advances in Hematology 2005. Hematopoietic Cell Transplantation for
`Hematopoietic Malignancies.
`
`12/05 American Society of Hematology, Atlanta, Georgia. Education Spotlight Session, “Cellular Therapy: Graft
`Engineering and Clinical Applications”.
`
`3/06 3rd Annual Symposium on Stem Cells, Mater Research Institute, Brisbane, Australia. “Vizualization of Immune
`Cell Trafficking in the Transplant Setting” and “Strategies to Limit Graft-vs-Host and Enhance Graft- vs-Tumor
`Reactions”.
`
`6/06
`
`FOCIS 2006, San Francisco, CA. The Role of Regulatory T Cells (T-Regs) in GVHD.
`
`10/06
`
`Institute of Medicine, Washington, DC. “Science to Clinic: Near Term”.
`
`10/06 University of North Carolina, Chapel Hill. Hematology/Oncology Grand Rounds. “Regulation of Immune
`Responses in Transplantation”.
`10/06 Hospital 307 of the PLA, Beijing, China. “Regulation of Immune Responses”.
`
`10/06 Chinese Society of Hematology, Nanjing, China. “Immune Regulation – Striking a Balance in Bone Marrow
`Transplantation”.
`
`10/06 Singapore General Hospital, Singapore. “Biology and Clinical Application of Cytokine Induced Killer Cells”.
`
`6
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UPenn Ex. 2066
`Miltenyi v. UPenn
`IPR2022-00855
`
`

`

`10/06 Singapore General Hospital, Singapore. “Immune Regulation – Striking a Balance in Bone Marrow
`Transplantation”.
`
`2/07 American Society of Blood and Marrow Transplantation, Keystone, Colorado. Plenary Session on Regulating
`T Cells: History, Laboratory and Clinical Uses. “The Promise and Challenges of Human Regulatory T Cells
`in the Clinic”.
`
`2/07 Memorial Sloan Kettering Cancer Center, Hematology/Oncology Grand Rounds, New York, New York.
`“Regulatory T cells”.
`
`4/07 City of Hope National Medical Center, Duarte, California. Gerhard Schmidt Memorial Lecture. “Immune
`Regulation: Striking the Balance in Allogeneic Transplantation”.
`
`5/07 Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas. “Immune Regulation in
`Hematopoietic Cell Transplantation”.
`
`9/07 11th Congress of the International Society of Hematology and 12th Congress of the Asian-Pacific Bone Marrow
`Transplantation, Beijing, China. Immune Regulatory Networks in the Post-Transplant Setting”. Cellular
`Immunotherapy for Hematologic Malignancies.
`
`10/07 5th Workshop on Haploidentical Stem Cell Transplantation, Catania, Italy. “Immune Regulatory Networks in
`the Post-Transplant Setting”.
`10/07 Sheba Medical Center, Sheba, Israel. “Imaging Graft-versus-Host and Graft-versus-Tumor Reactions”.
`
`Institute, Rehovet,
`10/07 Weitzman
`Transplantation”.
`
`Israel. “Regulation of
`
`Immune Responses n Hematopoietic Cell
`
`10/07 Royal Brisbane Hospital, Brisbane, Australia. “Biology of Regulatory T Cells”.
`
`10/07 HAA 2007, Gold Coast, Australia. “Immune Modulation and the Control of Graft-versus-Host Disease
`Following Non-Myeloablative Transplantation”.
`
`10/07 HAA 2007, Gold Coast, Australia. “Regulatory T Cells from Murine Models to the Clinic”.
`
`11/07
`
`Institute of Medical and Veterinary Science, Adelaide, Australia. “Biology of Regulatory T Cells”.
`
`11/07 Westmead Hospital, Sydney, Australia. “Regulatory T Cells from the Lab to the Clinic”.
`
`2/08 University of Pennsylvania, Philadelphia, PA. “Regulation of Immune Response in Hematopoietic Cell
`Transplantation”.
`
`2/08 American Society of Blood and Marrow Transplantation, San Diego, CA. “Reduced Intensity Conditioning
`Regimens: Where are we?”
`
`2/08 American Society of Blood and Marrow Transplantation, San Diego, CA. “Imaging Graft-versus-Host Reactions
`in Living Animals”.
`
`3/08 University of Nevada, Reno, Nevada. “Visualizing Immune Cell Trafficking in Transplantation to Explore Graft-
`versus-Host Disease and Graft-versus-Tumor Reactions”.
`
`9/08 2nd Annual Comprehensive Cancer Research Training Program, Stanford, CA. “Hematopoietic Cell
`Transplantation”.
`
`10/08 German Society of Hematology, Vienna, Austria. “Regulatory T cells in murine models of hematopoietic cell
`transplantation”.
`
`7
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UPenn Ex. 2066
`Miltenyi v. UPenn
`IPR2022-00855
`
`

`

`10/08 Division of Pulmonary and Critical Care, Stanford University. “Hematopoietic Cell Transplantation: Past,
`Present and Future”.
`
`2/09
`
`American Society of Blood and Marrow Transplantation, Tampa, Florida. “TLI/ATG Host Conditioning
`Protects from Graft-versus-host Disease while Maintaining Graft-versus-tumor Responses”.
`
`2/09 Distinguished Lecture in Immunology and Transplantation, M.D. Anderson Cancer Center, Houston, Texas.
`“Immune Regulation in Hematopoietic Cell Transplantation”.
`
`3/09 Cellular Therapy 2009, Nuremberg, Germany.
`Transplantation”.
`
`“Role of Regulatory T Cells in Hematopoietic Cell
`
`6/09
`
`Innovative Designs of Clinical Trials, Stanford, CA. “Regulatory T cells, from the Bench to the Bedside”.
`
`9/09 Malaysian Society of Hematology, Kuala Lumpur, Malaysia. “Reduced Intensity Conditioning in HSCT
`using Thymoglobulins – The Stanford Experience”.
`
`9/09
`
`Asian Pacific Transplant Forum, Kuala Lumpur, Malaysia.
`Transplantation”.
`
`“Combined Bone Marrow and Kidney
`
`10/09 Third Comprehensive Cancer Research Training Program (CCRTP) at Stanford University. “Hematopoietic
`Cell Transplantation for MDS and Leukemia”.
`
`11/09 NK2009, Freiburg, Germany. NK cells in Allogeneic Transplantation: A Novel Mechanism of Control of
`Graft-versus-Host Disease.
`
`12/09
`
`Introduction of Plenary Talk, Regulatory T Cells, American Society of Hematology, New Orleans, LA.
`
`12/09 Meet the Professor. “Regulatory T Cells”. American Society of Hematology, New Orleans, LA.
`
`5/10
`
`International Society of Cellular Therapy, Philadelphia, PA. Plenary Session I: Immune Regulatory Cells.
`
`9/10
`
`9/10
`
`6th International Symposium on Haploidentical Stem Cell Transplantation, Jerusalem, Israel. Translation of
`murine CD4+CD25+ Treg Studies to the Clinic.
`
`The First Comprehensive Cancer Research Training Program in Medical Oncology, Hinterzarten, Germany.
`Immune Regulation in Hematopoietic Cell Transplantation: From Mouse to Man.
`
`1/11 University of Pittsburg, Basic and Translational Research Conference.
`Hematopoietic Cell Transplantation: From Mouse to Man.
`
`Immune Regulation in
`
`2/11
`
`American Society of Blood and Marrow Transplantation, Honolulu, Hawaii. Regulatory T cells in Allogeneic
`HCT: From Mouse to Man.
`
`3/11
`
`Bridging the Gap 2011, Singapore. Optimizing Therapy for Graft-versus-Host Disease.
`
`3/11
`
`Acute Leukemia Forum 2011, San Francisco, CA. Have we made progress in the treatment of GVHD?
`
`9/11
`
`2/12
`
`Fifth Comprehensive Cancer Research Training Program at Stanford University.
`Immunotherapies.
`
`Cellular
`
`Bridging the Gap 2012, Hong Kong, China. Graft-vs-Host Disease: How far have we come with
`preventative strategies?
`
`6/12 University of California at Davis, Medical Grand Rounds. Allogeneic Hematopoietic Cell Transplantation
`Today and Tomorrow.
`
`8
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UPenn Ex. 2066
`Miltenyi v. UPenn
`IPR2022-00855
`
`

`

`7/12 Stanford University Medical Grand Rounds. Allogeneic Hematopoietic Cell Transplantation. Today and
`Tomorrow.
`
`7/12 Emory University Medical Grand Rounds. Allogeneic Hematopoietic Cell Transplantation. Today and
`Tomorrow.
`
`2/13 Keystone Meeting on Cancer Immunology and Immunotherapy, Vancouver, BC. Immunobiology of
`Hematopoietic Cell Transplantation.
`
`5/13 Distinguished Else-Kroner Lecture, Würzburg, Germany. Immunobiology of T Cells in Allogeneic
`Transplantation.
`
`5/13
`
`Advances in Allogeneic Stem Cell Transplantation, Freiburg, Germany. Immunobiology of T Cells in GVHD.
`
`5/13
`
`The Karl G. Blume – Gerhard Schmidt Memorial Lecture in Transplantation Biology and Medicine. City of
`Hope National Medical Center, Duarte, CA. GVHD from the Perspective of the T Cell.
`
`9/13 7th Comprehensive Cancer Research Traning Program at Stanford University. Biology and Use of
`Hematopoietic Cell Transplantation.
`
`2/14 American Society of Blood and Marrow Transplantation Annual Meeting, Dallas, Texas. Role of MRD in
`predicting outcomes for transplant in ALL.
`
`5/14 University of Michigan Cancer Center Grand Rounds, Ann Arbor, MI. Immune Regulation in Hematopoietic
`Cell Transplantation.
`
`7/14
`
`Training Course in Cellular Therapy, Murcia, Spain.
`
`9/14 CMC–Stanford Joint Symposium on Molecular Imaging, Seoul, South Korea. Understanding Graft-versus-
`Host Disease Through Imaging.
`
`9/14 Catholic University of Korea, Seoul, South Korea. Hematopoietic Cell Transplantation: The Stanford
`Experience.
`
`11/14 Recent Advances in Cancer Immunotherapy, Princess Takamatsu Symposium, Tokyo, Japan. Adoptive
`immunotherapy following allogeneic transplantation.
`
`8/15 Korean Society of Bone Marrow Transplantation, Kanju, South Korea. Reduced Intensity Allogeneic
`Transplantation with TLI and ATG: A Platform for Immunotherapy and Regulatory T Cell Networks in GVHD
`Suppression.
`
`9/15
`
`8th International Symposium on Haploidentical Transplantation, Parma, Italy. Regulatory T Cells.
`
`12/15 American Society of Hematology annual meeting, Orlando, Florida. GVHD vs GVL.
`
`4/16 American Association of Cancer Research annual meeting, New Orleans, LA. Deciphering Immune Responses
`Through Receptor Gene Imaging.
`
`8/16
`
`20th Congress of the Brazilian Society of Bone Marrow Transplantation, Fortaleza, Brazil. Role of
`Regulatory T Cells in Haploidentical Transplantation and Selecting Hematopoietic Stem Cell Donors.
`
`5/17 Dana Farber Cancer Institute, Boston, MA. Grand Rounds.
`
`5/17 Harvard Transfusion Medicine Grand Rounds, Boston, MA.
`
`7/17
`
`Lu Daopei Research Conference, Beijing, China. GVHD v. GVL.
`
`9
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UPenn Ex. 2066
`Miltenyi v. UPenn
`IPR2022-00855
`
`

`

`9/17
`
`1/18
`
`2/18
`
`4/18
`
`5/18
`
`10th Comprehensive Cancer Research Training Program, Stanford, CA. Plenary Lecture – Immune
`Regulation in HCT.
`
`9th International Symposium on Haploidentical HSC, Rehovet, Israel. Immunoregulatory strategies to
`control GVHD.
`
`E. Donnall Thomas Lecture, American Society of Blood and Marrow Transplantation Meetings, Salt Lake
`City, Utah.
`
`5th Annual Karl G. Blume Memorial Lecture, Stanford, CA. “What would Karl do? 30 years of BMT at
`Stanford”, Stanford, CA.
`
`Stanford cancer Immunotherapy and Blood and Marrow Transplant Symposium 2018. Understanding the
`Biology of GVHD, Stanford, CA.
`
`6/18 Richard O’Reiolly Lectureship, Memorial Sloan Kettering Cancer Center, New York, NY.
`
`9/18
`
`3rd Symposium of Art of Blood and Marrow Transplantation. Immune Regulation in Allogeneic
`Hematopoietic Cell Transplantation, Beijing, China.
`
`4/19 Masonic Cancer Center, University of Minnesota Seminar Series. Immune Regulation as a Strategy to
`Improve Outcomes Following Allogeneic Transplantation. Minneapolis, MN.
`
`7/19
`
`7th Lu Daopei Hematology Forum. Immune Regulation as a Strategy to Improve Outcomes Following
`Allogeneic Transplantation. Beijing, China.
`
`7/19
`
`Peking University. CAR T-Cell Therapy for Non-Hodgkins Lymphoma. Beijing, China.
`
`Journal Reviewer:
`
`Acta Hematologica
`Blood
`Bone Marrow Transplantation
`Experimental Hematology
`International Journal of Cancer
`Journal of Clinical Oncology
`Journal of Hematotherapy
`Journal of Clinical Investigation
`Nature/Medicine
`Biology of Blood and Marrow Transplantation
`Proceedings of the National Academy of Sciences
`Journal of Experimental Medicine
`
`Peer-Reviewed Publications:
`
`P-1.
`
`Negrin, R.S. and Neilands, J.B. Ferrichrome transport in inner membrane vesicles of Escherichia coli,
`K12. J. Biol. Chem. 253:2339-2342, 1978.
`
`P-2. Negrin, R.S., Foster, D.L. and Fillingame, R.H. Energy transducing H+-ATPase of Escherichia coli,
`reconstitution of proton translocating activity of the intrinsic membrane sector. J. Biol. Chem. 255:5643-
`5648, 1980.
`
`10
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UPenn Ex. 2066
`Miltenyi v. UPenn
`IPR2022-00855
`
`

`

`P-3.
`
`P-4.
`
`Fillingame, R.H., Mosher, M.E., Negrin, R.S. and Peters, L.K. H+-ATPase of Escherichia coli. UncB402
`mutation leads to loss of X subunit of Fo sector. J. Biol. Chem. 258:604-609, 1983.
`
`Duncan, S.R., Negrin, R.S., Mihm, F.G., Guilleminault, C. and Raffin, T.A. Nasal continuous positive
`airway pressure in the treatment of atelectasis. Chest 92:621-624, 1987.
`
`P-5. Negrin, R.S., Haeuber, D.H., Nagler, A., Olds, L.S., Donlon, T., Souza, L.M. and Greenberg, P.L. Treatment
`of myelodysplastic syndromes with recombinant human granulocyte colony stimulating factor. Ann. Int.
`Med. 110:976-984, 1989.
`
`P-6.
`
`Schmidt-Wolf, I.W.H., Aihara, M., Negrin, R.S., Blume, K.G. and Chao, N.J. Lymphokine-activated killer
`cell activity after cryopreservation. J. Immunol. Methods 125:185-189, 1989.
`
`P-7. Nagler, A., Ginzton, N., Negrin, R.S., Bangs, C., Donlon, T. and Greenberg, P.L. Effects of recombinant human
`granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro
`hemopoiesis in the myelodysplastic syndromes. Leukemia 4:193-202, 1990.
`
`P-8.
`
`Negrin, R.S., Haeuber, D.H., Nagler, A., Kobayashi, Y., Sklar, J., Donlon, T., Vincent, M. and Greenberg,
`P.L. Maintenance treatment of patients with myelodysplastic syndromes with recombinant human
`granulocyte colony stimulating factor. Blood 76:36-43, 1990.
`
`P-9. Nagler, A., Binet, C., Mackichan, M.L., Negrin, R.S., Bangs, C., Donlon, T. and Greenberg, P.L. Impact of
`marrow cytogenetics and morphology on in vitro hemopoiesis in the myelodysplastic syndromes:
`Comparison between recombinant human granulocyte colony stimulating factor and granulocyte-monocyte
`colony stimulating factor. Blood 76:1299-1307, 1990.
`
`P-10. Negrin, R.S., Kiem, H.P., Schmidt-Wolf, I.W.H., Blume, K.G. and Cleary, M. Use of the polymerase chain
`reaction to monitor the effectiveness of ex vivo tumor cell purging. Blood 77:654-660, 1991.
`
`P-11. Negrin, R.S. and Blume, K.G. The use of the polymerase chain reaction for the detection of minimal
`residual malignant disease. Blood 78:255-258, 1991.
`
`P-12. Schmidt-Wolf, I.G.H., Negrin, R.S., Kiem, H.P., Blume, K.G. and Weissman, I.L. Use of a SCID mouse/human
`lymphoma model to evaluate cytokine induced killer cells with potent anti-tumor cell activity. J. Exp. Med.
`174:139-149, 1991.
`
`P-13. Schmidt-Wolf, I.G.H., Aihara, M., Negrin, R.S., Blume, K.G. and Chao, N.J. In vitro and in vivo activity of
`murine lymphokine-activated killer cells after cryopreservation. Transfusion 32:42-45, 1992.
`
`P-14. Chao, N.J., Tierney, D.K., Bloom, J.R., Long, G.D., Barr, T.A., Stallbaum, B.A., Wong, R.M., Negrin, R.S.,
`Horning, S.J. and Blume, K.G. Dynamic assessment of quality of life after autologous bone marrow
`transplantation. Blood 80:825-830, 1992.
`
`P-15. Negrin, R.S. and Greenberg, P.L. Therapy of hematopoietic disorders with recombinant colony stimulating
`factors. Advances in Pharm 23:263-296, 1992.
`
`P-16. Chao, N.J., Long, G.D., Negrin, R.S., Schriber, J.R., Raimonda, C.M., Brown, S.L. and Blume, K.G. G-
`CSF and peripheral blood progenitor cells. Lancet 339:1410-1411, 1992.
`
`P-17. Negrin, R.S. and Greenberg, P.L. The use of colony stimulating factors in clinical bone marrow
`transplantation. Current Opinion in Immunology, 4:567-570, 1992.
`
`P-18. Negrin, R.S. Use of the polymerase chain reaction for the detection of tumor cell involvement of bone
`marrow and peripheral blood: implications for purging. Journal of Hematotherapy 1:361-368, 1992.
`
`11
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UPenn Ex. 2066
`Miltenyi v. UPenn
`IPR2022-00855
`
`

`

`P-19. Chao, N.J., Stein, A.S., Long, G.D., Negrin, R.S., Amylon, M.D., Wong, R.M., Forman, S.J. and Blume,
`K.G. Busulfan/Etoposide - Initial experience with a new preparatory regimen for autologous bone marrow
`transplantation in patients with acute nonlymphoblastic leukemia. Blood 81:319-323, 1993.
`
`P-20. Chao, N.J., Schriber, J.R., Grimes, K., Long, G.D., Negrin, R.S., Raimondi, C.M., Horning, S.J., Brown, S.O.,
`Miller, L. and Blume, K.G. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor
`cells accelerate granulocyte and platelet recovery after high dose chemotherapy. Blood 81:2031-2035,
`1993.
`
`P-21. Schriber, J.R. and Negrin, R.S. Use and toxicity of the colony stimulating factors. Drug Safety 8:457-468,
`1993.
`
`P-22. Negrin, R.S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J., Krantz, S. and Greenberg, P.L. Treatment of
`the anemia of myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor
`in combination with erythropoietin. Blood, 82:737-743, 1993.
`
`P-23. Chao, N.J., Schmidt, G.M., Niland, J.C., Amylon, M.D., Dagis, A.C., Long, G.D., Nademanee, A.P., Negrin,
`R.S., O'Donnell, M.R., Parker, P.M., Smith, E.P., Snyder, D.S., Stein, A.S., Wong, R.M., Blume, K.G. and
`Forman, S.J. Cyclosporine, methotrexate and prednisone compared with cyclosporine and prednisone for
`prophylaxis of acute graft-versus-host disease. New England Journal of Medicine, 329:1225-1230, 1993.
`
`P-24. Snyder, D.S., Chao, N.J., Amylon, M.D., Taguchi, J., Long, G.D., Negrin, R.S., Nademanee, A.P.,
`O'Donnell, M.R., Schmidt, G.M., Stein, A.S., Parker, P.M., Smith, E.P., Stepan, D.E., Molina, A., Lipsett,
`J.A., Hoppe, R.T., Niland, J.C., Dagis, A.C., Wong, R.M., Forman, S.J. and Blume, K.G. Fractionated total
`body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99
`patients with acute leukemia in first complete remission. Blood, 82:2920-2928, 1993.
`
`P-25. Schriber, J.R., Negrin, R.S., Chao, N.J., Long, G.D., Horning, S.J. and Blume, K.G. The efficacy of
`granulocyte-colony stimulating factor following autologous bone marrow transplantation for non-Hodgkin's
`lymphoma with monoclon